Table 4.
Odds ratios (95%CI) for the association with left ventricular reverse remodeling
| Variables | Univariate | Multivariatea | |
|---|---|---|---|
| model 1 | model 2 | ||
| Age | 0.99 (0.91–1.08) | ||
| Male Sex | 0.38 (0.27–5.17) | ||
| Disease duration (months) | 0.98 (0.96–1.01) | ||
| Height (cm) | 0.94 (0.81–1.09) | ||
| Weight (kg) | 0.97 (0.88–1.07) | ||
| HR (bpm) | 1.01 (0.97–1.06) | ||
| Beta-blocker | 0.88 (0.05–16.74) | ||
| ACEI or ARB | 0.38 (0.03–5.17) | ||
| Inotropes | 0.04 (0.003–0.57)* | 0.002 (0.001–18.0) | 0.06 (0.001–2.95) |
| Hb (g/dL) | 1.44 (0.86–2.41) | ||
| Cre (mg/dl) | 0.05 (0.003–1.06) | ||
| BNP (pg/ml) | 1.00 (0.99–1.01) | ||
| LVDD (mm) | 0.94 (0.85–1.03) | ||
| LVEF (%) | 1.06 (0.85–1.32) | ||
| LAD (mm) | 0.96 (0.86–1.06) | ||
| AR (moderate to severe) | 1.77 (0.74–4.23) | ||
| MR (moderate to severe) | 0.61 (0.20–1.93) | ||
| TR (moderate to severe) | 0.70 (0.26–1.89) | ||
| PAP, mean (mmHg) | 0.97 (0.88–1.08) | ||
| PCWP, mean (mmHg) | 0.96 (0.84–1.10) | ||
| RAP, mean (mmHg) | 0.80 (0.57–1.12) | ||
| CI (L/min/m2) | 4.75 (0.35–63.67) | ||
| PVR (Wood) | 0.98 (0.53–1.83) | ||
| NDUFS5 (per 100FPKM) | 0.07 (0.01–0.92)* | 0.007 (0.001–7.24) | |
| GADD45G (per 10FPKM) | 0.28 (0.09–0.89)* | 0.38 (0.13–1.07) | |
Abbreviations: HR heart rate; ACEI angiotensin converting enzyme inhibitor; ARB angiotensin II receptor blocker; Hb hemoglobin; Cre creatinine; LVDD left ventricular diastolic diameter; LVEF left ventricular ejection fraction; LAD left atrial diameter; AR aortic regurgitation; MR mitral regurgitation; TR tricuspid regurgitation; PAP pulmonary artery pressure; PCWP pulmonary capillary wedge pressure; RAP right atrial pressure; CI cardiac index; PVR pulmonary vascular resistance
aConfounders with p values < 0.05 in each analysis group were included into the model
*p < 0.05